bioMérieux S.A. (EPA:BIM)
France · Delayed Price · Currency is EUR | Market Cap | 8.39B -38.9% |
| Revenue (ttm) | 4.07B +2.3% |
| Net Income | 397.50M -8.0% |
| EPS | 3.34 -8.2% |
| Shares Out | 117.95M |
| PE Ratio | 21.29 |
| Forward PE | 15.84 |
| Dividend | 0.98 (1.38%) |
| Ex-Dividend Date | Jun 9, 2026 |
| Volume | 217,780 |
| Average Volume | 265,280 |
| Open | 71.30 |
| Previous Close | 71.10 |
| Day's Range | 71.30 - 72.60 |
| 52-Week Range | 68.05 - 128.30 |
| Beta | 0.54 |
| RSI | 31.03 |
| Earnings Date | Jul 28, 2026 |
About bioMérieux
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of... [Read more]
Financial Performance
In 2025, bioMérieux's revenue was 4.07 billion, an increase of 2.26% compared to the previous year's 3.98 billion. Earnings were 397.50 million, a decrease of -8.03%.
Financial StatementsNews
bioMerieux price target lowered to EUR 71.60 from EUR 120.50 at JPMorgan
JPMorgan lowered the firm’s price target on bioMerieux (BMXMF) to EUR 71.60 from EUR 120.50 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate
bioMerieux downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Jan Koch downgraded bioMerieux (BMXMF) to Hold from Buy with a price target of EUR 81, down from EUR 120. The firm views the company’s profit warning
bioMérieux Earnings Call Transcript: Q1 2026
Q1 2026 saw a 3.9% sales decline due to weak respiratory demand and geopolitical headwinds, but core reagent growth remained strong. Guidance for 2026 was revised down to 3%-5% sales growth and 0%-10% EBIT improvement, with cost controls and innovation initiatives ongoing.
BioMerieux Q1 Sales Down 3.9% On Organic Basis; Revises 2026 Guidance
(RTTNews) - BioMerieux (EYWN.MU, BIM.PA) reported first quarter consolidated sales of 984 million euros, down 10.4% as reported from last year. On an organic basis, sales were down 3.9%. The company s...
bioMerieux price target lowered to EUR 100 from EUR 108 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on bioMerieux (BMXMF) to EUR 100 from EUR 108 and keeps an Equal Weight rating on the shares. Published first on TheFly –
bioMérieux Earnings Call Transcript: H2 2025
Sales grew 6.2% organically to €4 billion in 2025, with EBIT up 16% and strong cash flow. 2026 guidance targets 5–7% sales growth and at least 10% EBIT growth, despite headwinds from China and currency. Price erosion remains limited and new launches are expected to drive future growth.
bioMerieux price target lowered to EUR 100 from EUR 110 at Barclays
Barclays lowered the firm’s price target on bioMerieux (BMXMF) to EUR 100 from EUR 110 and keeps an Equal Weight rating on the shares. Published first on TheFly – the
bioMerieux price target lowered to EUR 109 from EUR 112 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on bioMerieux (BMXMF) to EUR 109 from EUR 112 and keeps an Equal Weight rating on the shares. Published first
bioMerieux downgraded to Neutral from Outperform at BNP Paribas
BNP Paribas analyst Hugo Solvet downgraded bioMerieux (BMXMF) to Neutral from Outperform with a EUR 100 price target Published first on TheFly – the ultimate source for real-time, market-moving breaki...
bioMerieux price target lowered to EUR 112 from EUR 113 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on bioMerieux (BMXMF) to EUR 112 from EUR 113 and keeps an Equal Weight rating on the shares. Published first
bioMerieux upgraded to Neutral from Underperform at BofA
BofA upgraded bioMerieux (BMXMF) to Neutral from Underperform with a price target of EUR 115, up from EUR 90. The firm thinks competitive headwinds are reflected in estimates, that internal